Claims for Patent: 9,017,687

Summary for Patent: 9,017,687

Title:	Low acidic species compositions and methods for producing and using the same using displacement chromatography
Abstract:	The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF.alpha. is detrimental, are also provided.
Inventor(s):	Wang; Chen (Shrewsbury, MA), Coppola; Germano (Shrewsbury, MA), Chumsae; Chris (North Andover, MA)
Assignee:	AbbVie, Inc. (North Chicago, IL)
Application Number:	14/079,076
Patent Claims:	1. A method for producing a low acidic species adalimumab composition, the method comprising: (a) contacting a first composition comprising adalimumab with a chromatography media, wherein the first composition comprises more than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab have a net negative charge relative to adalimumab main species, wherein the acidic species of adalimumab comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants, and any combinations thereof, wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components, and wherein the adalimumab binds to the chromatography media; (b) displacing the adalimumab bound to the chromatography media with a displacing buffer; and (c) collecting a second composition comprising the displaced adalimumab, wherein the second composition comprises less than 10% total acidic species of adalimumab, thereby producing a low acidic species adalimumab composition. 2. The method of claim 1, wherein the pH of the displacing buffer is lower than the isoelectric point of adalimumab. 3. The method of claim 1, wherein the displacing buffer carries a positive charge. 4. The method of claim 1, wherein the conductivity of the displacing buffer is about 2 mS/cm to about 20 mS/cm. 5. The method of claim 1, wherein one displacing buffer is used. 6. The method of claim 1, wherein displacing the adalimumab bound to the chromatography media comprises using a first displacing buffer followed by using a second displacing buffer. 7. The method of claim 1, wherein displacing is achieved using linear displacement. 8. The method of claim 1, wherein the second composition comprises less than 9% total acidic species of adalimumab. 9. The method of claim 1, wherein the second composition comprises less than 8% total acidic species of adalimumab. 10. The method of claim 1, wherein the second composition comprises less than 7% total acidic species of adalimumab. 11. The method of claim 1, wherein the second composition comprises less than 6% total acidic species of adalimumab. 12. The method of claim 1, wherein the second composition comprises less than 5% total acidic species of adalimumab. 13. The method of claim 1, wherein the second composition comprises less than 4.5% total acidic species of adalimumab. 14. The method of claim 1, wherein the second composition comprises less than 4% total acidic species of adalimumab. 15. The method of claim 1, wherein the second composition comprises less than 3% total acidic species of adalimumab. 16. The method of claim 1, wherein the second composition comprises less than 1.4% total acidic species of adalimumab. 17. The method of claim 1, wherein the displacing buffer comprises protamine sulfate. 18. The method of claim 1, wherein the displacing buffer comprises a quaternary ammonium salt. 19. The method of claim 1, wherein the chromatography media is an anion exchange adsorbent material. 20. The method of claim 1, wherein the chromatography media is a cation exchange adsorbent material. 21. The method of claim 20, wherein the cation exchange adsorbent material is a CEX resin or a CEX membrane adsorber. 22. The method of claim 20, wherein the cation exchange adsorbent material is a CEX resin. 23. The method of claim 1, wherein the chromatography media is a mixed mode media comprising cation exchange and hydrophobic interaction functional groups. 24. The method of claim 1, wherein the chromatography media is a mixed mode media selected from the group consisting of a cation exchange-based mixed mode resin and a cation-exchange-based mixed mode membrane adsorber. 25. The method of claim 1, wherein the displacing buffer comprises protamine sulfate, a quaternary ammonium salt, a polyelectrolyte, a polysaccharide, a low-molecular-mass dendrimer, an amino acid, a peptide, an antibiotic, a polyaromatic polyanionic compound, or an aminoglycosidepolyamine. 26. The method of claim 25, wherein the concentration of the protamine sulfate, quaternary ammonium salt, polyelectrolyte, polysaccharide, low-molecular-mass dendrimer, amino acid, peptide, antibiotic, polyaromatic polyanionic compound, or aminoglycosidepolyamine in the displacing buffer is 0.1 mM to 10 mM. 27. The method of claim 1, wherein displacing is achieved using a two-step displacement. 28. The method of claim 1, wherein displacing is achieved using a multiple-step displacement.

Details for Patent 9,017,687

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2033-03-14
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2033-03-14
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2033-03-14
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2033-03-14
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2033-03-14
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2033-03-14